{"protocolSection": {"identificationModule": {"nctId": "NCT02288819", "orgStudyIdInfo": {"id": "ZOL-DIPSTICK"}, "organization": {"fullName": "Hasselt University", "class": "OTHER"}, "briefTitle": "Spot Urinary Analysis to Assess Loop Diuretic Efficiency in Stable Heart Failure", "officialTitle": "Diuretic Efficiency in Patients With Stable Heart Failure: Ion Excretion Capacity of the Kidneys (DIPSTICK) Study", "acronym": "DIPSTICK"}, "statusModule": {"statusVerifiedDate": "2019-01", "overallStatus": "TERMINATED", "whyStopped": "Slow recruitment and a lack of funding to complete further follow-up", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-09"}, "primaryCompletionDateStruct": {"date": "2016-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-10-23", "studyFirstSubmitQcDate": "2014-11-07", "studyFirstPostDateStruct": {"date": "2014-11-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-10-24", "resultsFirstSubmitQcDate": "2019-01-15", "resultsFirstPostDateStruct": {"date": "2019-04-16", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-01-15", "lastUpdatePostDateStruct": {"date": "2019-04-16", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Wilfried Mullens, MD PhD", "investigatorTitle": "Prof. Dr.", "investigatorAffiliation": "Ziekenhuis Oost-Limburg"}, "leadSponsor": {"name": "Hasselt University", "class": "OTHER"}, "collaborators": [{"name": "Ziekenhuis Oost-Limburg", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The primary objective of this study is to assess whether the urinary sodium/creatinine or chloride/creatinine ratio might predict successful downtitration of loop diuretics in patients with stable heart failure without clinical signs of volume overload. In addition, this study will provide information on loop diuretic efficiency and urinary electrolyte composition after intake of diuretics in stable outpatients with heart failure."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["loop diuretics", "heart failure", "natriuresis", "urinary analysis"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 50, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Loop diuretic downtitration", "type": "EXPERIMENTAL", "description": "Scheduled downtitration of maintenance loop diuretic dose while monitoring weight", "interventionNames": ["Device: Weight monitoring", "Drug: Loop diuretic downtitration"]}], "interventions": [{"type": "DEVICE", "name": "Weight monitoring", "description": "The body weight of patients is measured each morning in identical conditions on the same balance during 7 days", "armGroupLabels": ["Loop diuretic downtitration"]}, {"type": "DRUG", "name": "Loop diuretic downtitration", "description": "The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.\n\nIn case of a total daily maintenance dose \u226440 mg furosemide OR \u22641 mg bumetanide OR \u226420 mg torsemide, the loop diuretic is completely stopped.\n\nIn case of a total daily maintenance dose \\>40 mg furosemide OR \\>1 mg bumetanide OR \\>20 mg torsemide, the loop diuretic dose is halved.", "armGroupLabels": ["Loop diuretic downtitration"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Successful Downtitration of Loop Diuretics (no Weight Increase >1,5 kg)", "description": "After baseline evaluation, loop diuretics are temporarily downtitrated or stopped for 7 consecutive days. The patient is instructed to measure his/her weight in the morning of these days, immediately after waking up, on the same balance. In case of weight increase \\>1,5 kg, the original dose of diuretics is restored. To check this, patients are contacted by phone after 3 and 7 days. If the patient has not gained \\>1,5 kg of weight after 7 days, loop diuretics are considered to be successfully downtitrated.", "timeFrame": "7 days after baseline"}], "secondaryOutcomes": [{"measure": "All-cause Mortality", "timeFrame": "30 days after baseline"}, {"measure": "Number of Participants Rehospitalized for Heart Failure", "description": "Unplanned hospital admission for symptoms of congestion and/or low output heart failure requiring either intravenous therapy and/or increase of oral diuretics.", "timeFrame": "30 days after baseline"}, {"measure": "Number of Participants Requiring a Dose Increase in Loop Diuretics", "description": "Dose increase of oral maintenance therapy with loop diuretics compared to the final dose achieved in the study 7 days after baseline.", "timeFrame": "30 days after baseline"}, {"measure": "Weight Change", "description": "Weight change \\[kg\\] 7 days after baseline compared to baseline weight.", "timeFrame": "7 days after baseline"}], "otherOutcomes": [{"measure": "Weight Change", "description": "Weight change \\[kg\\] 30 days after baseline compared to weight 7 days after baseline (after achieving the final dose of loop diuretics).", "timeFrame": "30 days after baseline"}, {"measure": "Self-reported Orthopnea", "description": "The patient is contacted by phone 30 days after baseline and asked for self-reported orthopnea.", "timeFrame": "30 days after baseline"}, {"measure": "Self-reported Lower Leg Edema", "description": "The patient is contacted by phone 30 days after baseline and asked for self-reported presence of lower leg edema.", "timeFrame": "30 days after baseline"}, {"measure": "New York Heart Association (NYHA) Functional Class", "description": "NYHA class is a semi-quantitative measurement of functional capacity on a scale from 1 to 4:\n\n1. No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).\n2. Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).\n3. Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.\n4. Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.\n\nFor the purpose of this outcome parameter, the patient is contacted by phone 30 days after baseline and NYHA functional class is assessed by a study investigator.", "timeFrame": "30 days after baseline"}, {"measure": "All-cause Mortality", "timeFrame": "6 months after baseline"}, {"measure": "Rehospitalization for Heart Failure", "description": "Unplanned hospital admission for symptoms of congestion and/or low output heart failure requiring either intravenous therapy and/or increase of oral diuretics.", "timeFrame": "6 months after baseline"}, {"measure": "Dose Increase of Loop Diuretics", "description": "Dose increase of oral maintenance therapy with loop diuretics compared to the final dose achieved in the study 7 days after baseline.", "timeFrame": "6 months after baseline"}, {"measure": "Weight Change", "description": "Weight change \\[kg\\] 7 days after baseline compared to baseline weight.", "timeFrame": "7 days after baseline"}, {"measure": "NYHA Functional Class", "description": "The patient is contacted by phone 30 days after baseline and NYHA functional class is assessed by a study investigator.", "timeFrame": "30 days after baseline"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient has a left ventricular ejection fraction \\<40% or has been previously hospitalized with a primary diagnosis of heart failure\n* Patient receives a daily maintenance dose of loop diuretics\n\nExclusion Criteria:\n\n* Patient was hospitalized for heart failure \\<3 months before study inclusion\n* The maintenance dose of loop diuretics was changed \\<3 months before study inclusion\n* The maintenance dose of renin-angiotensin-aldosterone system blockers or beta-blocker medication was changed \\<3 months before study inclusion\n* Cardiac resynchronization therapy (CRT) was initiated \\<3 months before study inclusion\n* At the moment of inclusion, the patient has either one of the following signs of volume overload: lower leg edema +2/4, ascites, lung congestion\n* Patient is not able to measure his/her weight safely and correct at home", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Wilfried Mullens, M.D. Ph.D.", "affiliation": "Ziekenhuis Oost-Limburg", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Frederik H Verbrugge, M.D. Ph.D.", "affiliation": "Ziekenhuis Oost-Limburg", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Ziekenhuis Oost-Limburg", "city": "Genk", "state": "Limburg", "zip": "3600", "country": "Belgium", "geoPoint": {"lat": 50.965, "lon": 5.50082}}]}, "referencesModule": {"references": [{"pmid": "29056238", "type": "RESULT", "citation": "Martens P, Verbrugge FH, Boonen L, Nijst P, Dupont M, Mullens W. Value of routine investigations to predict loop diuretic down-titration success in stable heart failure. Int J Cardiol. 2018 Jan 1;250:171-175. doi: 10.1016/j.ijcard.2017.10.018. Epub 2017 Oct 6."}, {"pmid": "28971753", "type": "RESULT", "citation": "Verbrugge FH, Martens P, Boonen L, Nijst P, Verhaert D, Noyens P, De Vusser P, Dupont M, Tang WHW, Mullens W. Loop diuretic down-titration in stable chronic heart failure is often achievable, especially when urinary chloride concentration is low. Acta Cardiol. 2018 Aug;73(4):335-341. doi: 10.1080/00015385.2017.1385152. Epub 2017 Oct 3."}, {"pmid": "27594125", "type": "RESULT", "citation": "Boonen L, Verbrugge FH, Nijst P, Noyens P, De Vusser P, Verhaert D, Van Lierde J, Vrolix M, Dupont M, Mullens W. Subclinical volume overload in stable outpatients with chronic heart failure. Acta Cardiol. 2016 Jun;71(3):299-307. doi: 10.2143/AC.71.3.3152090. No abstract available."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Outpatient cardiology clinic of a single tertiary centre (Ziekenhuis Oost-Limburg, Genk, Belgium) between December, 2014, and February, 2016.", "groups": [{"id": "FG000", "title": "Loop Diuretic Downtitration", "description": "Scheduled downtitration of maintenance loop diuretic dose while monitoring weight\n\nWeight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days\n\nLoop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.\n\nIn case of a total daily maintenance dose \u226440 mg furosemide OR \u22641 mg bumetanide OR \u226420 mg torsemide, the loop diuretic is completely stopped.\n\nIn case of a total daily maintenance dose \\>40 mg furosemide OR \\>1 mg bumetanide OR \\>20 mg torsemide, the loop diuretic dose is halved."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "50"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "50"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Loop Diuretic Downtitration", "description": "Scheduled downtitration of maintenance loop diuretic dose while monitoring weight\n\nWeight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days\n\nLoop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.\n\nIn case of a total daily maintenance dose \u226440 mg furosemide OR \u22641 mg bumetanide OR \u226420 mg torsemide, the loop diuretic is completely stopped.\n\nIn case of a total daily maintenance dose \\>40 mg furosemide OR \\>1 mg bumetanide OR \\>20 mg torsemide, the loop diuretic dose is halved."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "50"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "73", "lowerLimit": "61", "upperLimit": "78"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "20"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "30"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "50"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Belgium", "categories": [{"measurements": [{"groupId": "BG000", "value": "50"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Successful Downtitration of Loop Diuretics (no Weight Increase >1,5 kg)", "description": "After baseline evaluation, loop diuretics are temporarily downtitrated or stopped for 7 consecutive days. The patient is instructed to measure his/her weight in the morning of these days, immediately after waking up, on the same balance. In case of weight increase \\>1,5 kg, the original dose of diuretics is restored. To check this, patients are contacted by phone after 3 and 7 days. If the patient has not gained \\>1,5 kg of weight after 7 days, loop diuretics are considered to be successfully downtitrated.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "7 days after baseline", "groups": [{"id": "OG000", "title": "Loop Diuretic Downtitration", "description": "Scheduled downtitration of maintenance loop diuretic dose while monitoring weight\n\nWeight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days\n\nLoop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.\n\nIn case of a total daily maintenance dose \u226440 mg furosemide OR \u22641 mg bumetanide OR \u226420 mg torsemide, the loop diuretic is completely stopped.\n\nIn case of a total daily maintenance dose \\>40 mg furosemide OR \\>1 mg bumetanide OR \\>20 mg torsemide, the loop diuretic dose is halved."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "37"}]}]}]}, {"type": "SECONDARY", "title": "All-cause Mortality", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "30 days after baseline", "groups": [{"id": "OG000", "title": "Loop Diuretic Downtitration", "description": "Scheduled downtitration of maintenance loop diuretic dose while monitoring weight\n\nWeight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days\n\nLoop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.\n\nIn case of a total daily maintenance dose \u226440 mg furosemide OR \u22641 mg bumetanide OR \u226420 mg torsemide, the loop diuretic is completely stopped.\n\nIn case of a total daily maintenance dose \\>40 mg furosemide OR \\>1 mg bumetanide OR \\>20 mg torsemide, the loop diuretic dose is halved."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Rehospitalized for Heart Failure", "description": "Unplanned hospital admission for symptoms of congestion and/or low output heart failure requiring either intravenous therapy and/or increase of oral diuretics.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "30 days after baseline", "groups": [{"id": "OG000", "title": "Loop Diuretic Downtitration", "description": "Scheduled downtitration of maintenance loop diuretic dose while monitoring weight\n\nWeight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days\n\nLoop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.\n\nIn case of a total daily maintenance dose \u226440 mg furosemide OR \u22641 mg bumetanide OR \u226420 mg torsemide, the loop diuretic is completely stopped.\n\nIn case of a total daily maintenance dose \\>40 mg furosemide OR \\>1 mg bumetanide OR \\>20 mg torsemide, the loop diuretic dose is halved."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Requiring a Dose Increase in Loop Diuretics", "description": "Dose increase of oral maintenance therapy with loop diuretics compared to the final dose achieved in the study 7 days after baseline.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "30 days after baseline", "groups": [{"id": "OG000", "title": "Loop Diuretic Downtitration", "description": "Scheduled downtitration of maintenance loop diuretic dose while monitoring weight\n\nWeight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days\n\nLoop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.\n\nIn case of a total daily maintenance dose \u226440 mg furosemide OR \u22641 mg bumetanide OR \u226420 mg torsemide, the loop diuretic is completely stopped.\n\nIn case of a total daily maintenance dose \\>40 mg furosemide OR \\>1 mg bumetanide OR \\>20 mg torsemide, the loop diuretic dose is halved."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Weight Change", "description": "Weight change \\[kg\\] 7 days after baseline compared to baseline weight.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kg", "timeFrame": "7 days after baseline", "groups": [{"id": "OG000", "title": "Loop Diuretic Downtitration", "description": "Scheduled downtitration of maintenance loop diuretic dose while monitoring weight\n\nWeight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days\n\nLoop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.\n\nIn case of a total daily maintenance dose \u226440 mg furosemide OR \u22641 mg bumetanide OR \u226420 mg torsemide, the loop diuretic is completely stopped.\n\nIn case of a total daily maintenance dose \\>40 mg furosemide OR \\>1 mg bumetanide OR \\>20 mg torsemide, the loop diuretic dose is halved."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.502", "spread": "1.101"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Weight Change", "description": "Weight change \\[kg\\] 30 days after baseline compared to weight 7 days after baseline (after achieving the final dose of loop diuretics).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kg", "timeFrame": "30 days after baseline", "groups": [{"id": "OG000", "title": "Loop Diuretic Downtitration", "description": "Scheduled downtitration of maintenance loop diuretic dose while monitoring weight\n\nWeight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days\n\nLoop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.\n\nIn case of a total daily maintenance dose \u226440 mg furosemide OR \u22641 mg bumetanide OR \u226420 mg torsemide, the loop diuretic is completely stopped.\n\nIn case of a total daily maintenance dose \\>40 mg furosemide OR \\>1 mg bumetanide OR \\>20 mg torsemide, the loop diuretic dose is halved."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.261", "spread": "1.391"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Self-reported Orthopnea", "description": "The patient is contacted by phone 30 days after baseline and asked for self-reported orthopnea.", "populationDescription": "1 patient who died before the 30-day follow-up could not be assessed", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "30 days after baseline", "groups": [{"id": "OG000", "title": "Loop Diuretic Downtitration", "description": "Scheduled downtitration of maintenance loop diuretic dose while monitoring weight\n\nWeight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days\n\nLoop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.\n\nIn case of a total daily maintenance dose \u226440 mg furosemide OR \u22641 mg bumetanide OR \u226420 mg torsemide, the loop diuretic is completely stopped.\n\nIn case of a total daily maintenance dose \\>40 mg furosemide OR \\>1 mg bumetanide OR \\>20 mg torsemide, the loop diuretic dose is halved."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Self-reported Lower Leg Edema", "description": "The patient is contacted by phone 30 days after baseline and asked for self-reported presence of lower leg edema.", "populationDescription": "1 patient who died before the 30-day follow-up could not be assessed", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "30 days after baseline", "groups": [{"id": "OG000", "title": "Loop Diuretic Downtitration", "description": "Scheduled downtitration of maintenance loop diuretic dose while monitoring weight\n\nWeight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days\n\nLoop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.\n\nIn case of a total daily maintenance dose \u226440 mg furosemide OR \u22641 mg bumetanide OR \u226420 mg torsemide, the loop diuretic is completely stopped.\n\nIn case of a total daily maintenance dose \\>40 mg furosemide OR \\>1 mg bumetanide OR \\>20 mg torsemide, the loop diuretic dose is halved."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "New York Heart Association (NYHA) Functional Class", "description": "NYHA class is a semi-quantitative measurement of functional capacity on a scale from 1 to 4:\n\n1. No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).\n2. Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).\n3. Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.\n4. Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.\n\nFor the purpose of this outcome parameter, the patient is contacted by phone 30 days after baseline and NYHA functional class is assessed by a study investigator.", "populationDescription": "1 patient who died before the 30-day follow-up could not be assessed", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale from 1 to 4", "timeFrame": "30 days after baseline", "groups": [{"id": "OG000", "title": "Loop Diuretic Downtitration", "description": "Scheduled downtitration of maintenance loop diuretic dose while monitoring weight\n\nWeight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days\n\nLoop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.\n\nIn case of a total daily maintenance dose \u226440 mg furosemide OR \u22641 mg bumetanide OR \u226420 mg torsemide, the loop diuretic is completely stopped.\n\nIn case of a total daily maintenance dose \\>40 mg furosemide OR \\>1 mg bumetanide OR \\>20 mg torsemide, the loop diuretic dose is halved."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.41", "spread": "0.57"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "All-cause Mortality", "populationDescription": "The study was terminated after every participant reached the 30-day follow-up point because of slow recruitment and a lack of funding to complete further follow-up", "reportingStatus": "POSTED", "timeFrame": "6 months after baseline", "groups": [{"id": "OG000", "title": "Loop Diuretic Downtitration", "description": "Scheduled downtitration of maintenance loop diuretic dose while monitoring weight\n\nWeight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days\n\nLoop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.\n\nIn case of a total daily maintenance dose \u226440 mg furosemide OR \u22641 mg bumetanide OR \u226420 mg torsemide, the loop diuretic is completely stopped.\n\nIn case of a total daily maintenance dose \\>40 mg furosemide OR \\>1 mg bumetanide OR \\>20 mg torsemide, the loop diuretic dose is halved."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Rehospitalization for Heart Failure", "description": "Unplanned hospital admission for symptoms of congestion and/or low output heart failure requiring either intravenous therapy and/or increase of oral diuretics.", "reportingStatus": "NOT_POSTED", "timeFrame": "6 months after baseline", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Dose Increase of Loop Diuretics", "description": "Dose increase of oral maintenance therapy with loop diuretics compared to the final dose achieved in the study 7 days after baseline.", "reportingStatus": "NOT_POSTED", "timeFrame": "6 months after baseline", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Weight Change", "description": "Weight change \\[kg\\] 7 days after baseline compared to baseline weight.", "reportingStatus": "NOT_POSTED", "timeFrame": "7 days after baseline", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Self-reported Orthopnea", "description": "The patient is contacted by phone 30 days after baseline and asked for self-reported orthopnea.", "reportingStatus": "NOT_POSTED", "timeFrame": "30 days after baseline", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Self-reported Lower Leg Edema", "description": "The patient is contacted by phone 30 days after baseline and asked for self-reported presence of lower leg edema.", "reportingStatus": "NOT_POSTED", "timeFrame": "30 days after baseline", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "NYHA Functional Class", "description": "The patient is contacted by phone 30 days after baseline and NYHA functional class is assessed by a study investigator.", "reportingStatus": "NOT_POSTED", "timeFrame": "30 days after baseline", "denomUnitsSelected": "Participants"}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "30 days", "eventGroups": [{"id": "EG000", "title": "Loop Diuretic Downtitration", "description": "Scheduled downtitration of maintenance loop diuretic dose while monitoring weight\n\nWeight monitoring: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days\n\nLoop diuretic downtitration: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.\n\nIn case of a total daily maintenance dose \u226440 mg furosemide OR \u22641 mg bumetanide OR \u226420 mg torsemide, the loop diuretic is completely stopped.\n\nIn case of a total daily maintenance dose \\>40 mg furosemide OR \\>1 mg bumetanide OR \\>20 mg torsemide, the loop diuretic dose is halved.", "deathsNumAffected": 1, "deathsNumAtRisk": 50, "seriousNumAffected": 1, "seriousNumAtRisk": 50, "otherNumAffected": 0, "otherNumAtRisk": 50}], "seriousEvents": [{"term": "Heart failure readmission", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Frederik Verbrugge", "organization": "Ziekenhuis Oost-Limburg", "email": "frederik.verbrugge@zol.be", "phone": "0473924199", "phoneExt": "+32"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M8219", "name": "Exanthema", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC17", "name": "Skin and Connective Tissue Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000004232", "term": "Diuretics"}, {"id": "D000049994", "term": "Sodium Potassium Chloride Symporter Inhibitors"}], "ancestors": [{"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M8784", "name": "Furosemide", "relevance": "LOW"}, {"id": "M5306", "name": "Bumetanide", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "asFound": "Scanner", "relevance": "HIGH"}, {"id": "M1912", "name": "Torsemide", "relevance": "LOW"}, {"id": "M26153", "name": "Sodium Potassium Chloride Symporter Inhibitors", "asFound": "Interleukin-6", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}]}}, "hasResults": true}